Enanta Pharmaceuticals (ENTA) Times Interest Earned (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Times Interest Earned of -$3.57 for Q1 2026, up 75.02% year-on-year from -$2.04 in Q1 2025, and up 2.08% on a QoQ basis from -$3.65 in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 10 years of Times Interest Earned data on file, last reported at -$3.57 in Q1 2026.
- For the quarter ending Q1 2026, Times Interest Earned rose 75.02% year-over-year to -$3.57; the trailing twelve-month figure through Mar 2026 stood at -$5.8 (up 51.05% YoY), and the FY2025 full-year result was -$11.11, changed 0.11% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$3.57, up from -$3.65 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$3.57 in Q1 2026 and bottomed at -$18.38 in Q2 2023.
- The 4-year median for Times Interest Earned is -$10.92 (2024), against an average of -$10.49.
- The widest annual swing landed in 2024, when Times Interest Earned decreased 18.36%; it then jumped 75.02% in 2026.
- A 4-year view of Times Interest Earned shows it stood at -$10.14 in 2023, then decreased by 18.36% to -$12.0 in 2024, then jumped by 69.58% to -$3.65 in 2025, then increased by 2.08% to -$3.57 in 2026.
- The last three Times Interest Earned figures came in at -$3.57 (Q1 2026), -$3.65 (Q4 2025), and -$7.7 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | -3.57 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.57 |
| Dec 31, 2025 | -3.65 |
| Sep 30, 2025 | -7.70 |
| Jun 30, 2025 | -11.68 |
| Mar 31, 2025 | -14.31 |
| Dec 31, 2024 | -12.00 |
| Sep 30, 2024 | -11.57 |
| Jun 30, 2024 | -10.27 |
| Mar 31, 2024 | -12.78 |
| Dec 31, 2023 | -10.14 |
| Sep 30, 2023 | -9.85 |
| Jun 30, 2023 | -18.38 |
| Dec 31, 2017 | 1,597.44 |
| Sep 30, 2017 | 6,032.78 |
| Jun 30, 2017 | -1,193.55 |
| Mar 31, 2017 | -1,188.25 |
| Dec 31, 2016 | -587.17 |
| Sep 30, 2016 | -281.73 |
| Jun 30, 2016 | -99.00 |
| Mar 31, 2016 | -51.36 |
| Dec 31, 2015 | 2,966.17 |
| Sep 30, 2015 | 1,837.00 |
| Jun 30, 2015 | 851.50 |
| Mar 31, 2015 | 24,280.50 |
| Dec 31, 2014 | 35,105.00 |
| Sep 30, 2014 | -1,331.50 |
| Jun 30, 2014 | 6,979.00 |
| Mar 31, 2014 | -1,281.75 |
| Dec 31, 2013 | -1,091.40 |
| Sep 30, 2013 | -587.63 |
| Jun 30, 2013 | -596.86 |
| Mar 31, 2013 | -444.56 |
| Dec 31, 2012 | 3,129.86 |